Literature DB >> 1705175

Covalent binding of human alpha 2-macroglobulin to deglycosylated ricin A chain and its immunotoxins.

M A Ghetie1, J W Uhr, E S Vitetta.   

Abstract

In this report we demonstrated that human alpha 2-macroglobulin (alpha 2M) reacts with deglycosylated ricin A chain (dgA) and its immunotoxins to form high molecular weight complexes (molecular mass approximately 800 kDa). This interaction has a t1/2 at 37 degrees C of 5 h and reaches completion at 24 h. Complexes of alpha 2M-dgA cannot be dissociated by guanidine, sodium dodecyl sulfate, or low pH, but can be partially dissociated by reducing agents, such as 2-mercaptoethanol in the presence of sodium dodecyl sulfate. This indicates that dgA or dgA-containing immunotoxins are bound to alpha 2M by disulfide bonds. The dgA-binding site on alpha 2M and the mechanism underlying its interaction with dgA are different from those described for proteases or methylamine. alpha 2M complexes do not bind to Blue-Sepharose 4B or anti-A chain-Sepharose, suggesting that the sites on dgA which bind Cibacron Blue or polyclonal anti-A chain antibodies are sterically blocked or modified by interaction with alpha 2M. The interaction of alpha 2M with dgA or its immunotoxins results in a 2- to 3-fold decrease in the activity of the dgA in both cell-free assays and cytotoxic assays. However 12 h after injection into mice, only 11% of immunotoxin was bound to alpha 2M because of the slow kinetics of the interaction versus the more rapid t1/2 of the immunotoxin in the circulation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1705175

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.

Authors:  Xiao-yun Liu; Laurentiu M Pop; John Schindler; Ellen S Vitetta
Journal:  MAbs       Date:  2012 Jan-Feb       Impact factor: 5.857

2.  Inhibition of a reductive function of the plasma membrane by bacitracin and antibodies against protein disulfide-isomerase.

Authors:  R Mandel; H J Ryser; F Ghani; M Wu; D Peak
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

Review 3.  Systemic immunotoxin therapy of cancer: advances and prospects.

Authors:  E J Wawrzynczak
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.